PUBLISHER: Grand View Research | PRODUCT CODE: 1869605
PUBLISHER: Grand View Research | PRODUCT CODE: 1869605
The global inhaled drugs contract manufacturing market size was estimated at USD 5.47 billion in 2024 and is projected to reach USD 12.56 billion by 2033, growing at a CAGR of 9.82% from 2025 to 2033. The market growth is driven due to the rising prevalence of respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD), which is fueling the demand for effective and targeted therapeutic options.
The growing clinical need, coupled with the expanding adoption of advanced inhalation therapies, is prompting pharmaceutical and biopharmaceutical companies to increasingly outsource drug development and manufacturing processes to specialized contract manufacturing, which is contributing to the growth of the inhaled drugs contract manufacturing industry.
In addition, the rising patient population suffering from chronic respiratory conditions, including asthma, COPD, among others, has accelerated the demand for effective inhalation therapies, including dry powder inhalers (DPIs), metered-dose inhalers (MDIs), and nebulizers. This growing therapeutic need is pushing pharmaceutical companies to expand their product pipelines and bring novel inhaled formulations to market faster. Developing these therapies requires specialized expertise in formulation, particle size optimization, and device compatibility, along with precision in dose delivery. Therefore, pharmaceutical companies are increasingly partnering with contract manufacturers organizations (CMOs) to leverage their technical capabilities, advanced infrastructure, and regulatory experience to enable faster development timelines and reduced capital expenditure. Thus, the aforementioned factors are driving the expansion of the inhaled drugs contract manufacturing market.
Furthermore, the need for cost optimization and operational efficiency is further accelerating the demand for contract manufacturing services in this market. Inhaled drug manufacturing involves high capital investment in device integration, cleanroom facilities, and aerosol testing, which can strain in-house resources. CDMOs with end-to-end capabilities, including formulation development, device engineering, and commercial-scale manufacturing, enable drug developers to minimize capital expenditure and accelerate time-to-market. This strategic outsourcing allows pharmaceutical companies to focus on core competencies such as research and marketing. At the same time, contract manufacturers benefit from long-term partnerships and recurring production contracts, contributing to sustained market growth.
Global Inhaled Drugs Contract Manufacturing Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global inhaled drugs contract manufacturing market report based on service, product, end-use, and region: